Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz, Momenta And Amphastar Settle US Enoxaparin Litigation

Executive Summary

Long-running US patent and antitrust litigation between Sandoz, Momenta and Amphastar over enoxaparin has been brought to an end after the parties agreed a settlement deal.

You may also be interested in...



Momenta Shelves Adalimumab But Persists With Aflibercept

Having failed to find a commercial partner, Momenta has halted development on its adalimumab biosimilar. But it is continuing to work on biosimilar aflibercept in conjunction with partner Mylan.

Amphastar Will Receive $59.9m In Momenta/Sandoz Settlement

The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement

The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel